WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 1767

Legislative bill overview

HB 1767 relates to opioid antagonists (medications like naloxone/Narcan that reverse opioid overdoses) in Hawaii. The bill has recently been introduced and referred to the Health and Consumer Protection committees, but specific provisions are not yet publicly detailed in the available information.

Why is this important

Opioid antagonist legislation typically addresses access, distribution, and training related to overdose reversal medications—critical tools in combating the ongoing opioid crisis. Hawaii, like other states, has faced rising opioid-related deaths, making policy around these life-saving medications a public health priority.

Potential points of contention

  • Scope of access: Disagreement over who can carry/administer naloxone (pharmacists, laypersons, first responders) and whether prescriptions should be required
  • Cost and insurance coverage: Whether antagonists are affordable and covered by insurance, or if public funding should subsidize distribution
  • Liability protections: Debate over legal immunity for individuals and organizations distributing or administering opioid antagonists in good faith

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.